TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,400,495 | +15.5% | 778,649 | +8.3% | 0.00% | 0.0% |
Q1 2024 | $5,542,465 | -58.6% | 718,867 | -51.8% | 0.00% | -50.0% |
Q4 2023 | $13,401,825 | -0.9% | 1,490,748 | -1.4% | 0.00% | -33.3% |
Q3 2023 | $13,518,058 | -4.7% | 1,512,087 | +63.7% | 0.00% | 0.0% |
Q2 2023 | $14,190,965 | -20.3% | 923,891 | +16.8% | 0.00% | -25.0% |
Q1 2023 | $17,794,717 | -68.0% | 791,228 | -70.0% | 0.00% | -71.4% |
Q4 2022 | $55,522,270 | +88128.6% | 2,640,146 | +3.4% | 0.01% | -12.5% |
Q3 2022 | $62,930 | -0.6% | 2,553,974 | -2.2% | 0.02% | 0.0% |
Q2 2022 | $63,305 | -99.9% | 2,612,646 | +0.9% | 0.02% | +14.3% |
Q1 2022 | $66,747,000 | -17.1% | 2,590,107 | -0.1% | 0.01% | -12.5% |
Q4 2021 | $80,510,000 | +203.7% | 2,593,757 | +137.2% | 0.02% | +166.7% |
Q3 2021 | $26,513,000 | -26.0% | 1,093,322 | -55.5% | 0.01% | -25.0% |
Q2 2021 | $35,852,000 | +73.5% | 2,457,280 | +197.0% | 0.01% | +60.0% |
Q1 2021 | $20,661,000 | +6.2% | 827,434 | +15.9% | 0.01% | 0.0% |
Q4 2020 | $19,459,000 | – | 713,966 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |